Next Article in Journal
The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers
Previous Article in Journal
Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue 5
10.3747/co.v16i5.385
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

131I–Tositumomab in Lymphoma

by
M. C. Cheung
1,2,
J. A. MacEachern
1,3,
A. E. Haynes
1,4,*,
R. M. Meyer
1,5,
K. Imrie
1,2,* and
the Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care
1
Cancer Care Ontario, Program in Evidence-Based Care, McMaster University, Hamilton, ON, Canada
2
Division of Hematology/Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
3
Division of Oncology, Grand River Regional Cancer Centre, Kitchener, ON, Canada
4
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
5
Divisions of Oncology, Medicine, and Community Health and Epidemiology, Queen’s University, Kingston, ON, Canada
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(5), 32-47; https://doi.org/10.3747/co.v16i5.385
Submission received: 4 June 2009 / Revised: 8 July 2009 / Accepted: 12 August 2009 / Published: 1 September 2009

Abstract

Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of 131I–tositumomab in non-Hodgkin lymphoma (nhl) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns about associated toxicities and unclear long-term benefit. Based on a comprehensive search for studies on 131I–tositumomab use in lymphoma, this systematic review summarizes and evaluates the evidence on (1) the benefits and risks of this novel therapy, (2) the predictors for response and toxicity, and (3) the role of dosimetry and imaging studies before treatment. We identified 18 trials investigating the use of 131I–tositumomab for the treatment of adult patients with nhl. In trials of patients with relapsed or refractory indolent nhl, overall response rates ranged from 67% to 83%. In patients with follicular nhl refractory to the monoclonal antibody rituximab, response rates remained high (65%–72%). However, in rituximabnaïve patients with relapsed or refractory indolent or transformed nhl, improvements in time to progression or survival have not been clearly established. 131I–Tositumomab is an active agent in relapsed and refractory non-Hodgkin lymphoma that should be considered in selected patients.
Keywords: 131I–Tositumomab; Bexxar; indolent lymphoma; systematic review 131I–Tositumomab; Bexxar; indolent lymphoma; systematic review

Share and Cite

MDPI and ACS Style

Cheung, M.C.; MacEachern, J.A.; Haynes, A.E.; Meyer, R.M.; Imrie, K.; , the Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 131I–Tositumomab in Lymphoma. Curr. Oncol. 2009, 16, 32-47. https://doi.org/10.3747/co.v16i5.385

AMA Style

Cheung MC, MacEachern JA, Haynes AE, Meyer RM, Imrie K, the Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 131I–Tositumomab in Lymphoma. Current Oncology. 2009; 16(5):32-47. https://doi.org/10.3747/co.v16i5.385

Chicago/Turabian Style

Cheung, M. C., J. A. MacEachern, A. E. Haynes, R. M. Meyer, K. Imrie, and the Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 2009. "131I–Tositumomab in Lymphoma" Current Oncology 16, no. 5: 32-47. https://doi.org/10.3747/co.v16i5.385

APA Style

Cheung, M. C., MacEachern, J. A., Haynes, A. E., Meyer, R. M., Imrie, K., & , the Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. (2009). 131I–Tositumomab in Lymphoma. Current Oncology, 16(5), 32-47. https://doi.org/10.3747/co.v16i5.385

Article Metrics

Back to TopTop